ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Alnylam To Cut A Third Of Staff

by Lisa M. Jarvis
January 30, 2012 | APPEARED IN VOLUME 90, ISSUE 5

Alnylam is making another round of job cuts as it sharpens its focus on the clinical development of its RNAi-based drug candidates. The Cambridge, Mass.-based company, which had 171 employees at the end of September 2011, will trim 33% of its workforce to save roughly $20 million this year. Alnylam will take a $4 million charge in the first quarter related to the restructuring. The move marks the second round of major layoffs at Alnylam, which in September 2010 shed a quarter of its staff after ending a five-year research collaboration with Novartis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment